ICO-ICS Praxi per al tractament mèdic i amb irradiació de càncer gàstric i d'unió esofagogàstrica

Tractament mèdic; Tractament amb irradiació; Càncer de la unió esofagogàstricaTratamiento médico; Tratamiento con irradiación; Cáncer de la unión esofagogástricaMedical treatment; Irradiation treatment; Esophagogastric union cancerEl càncer gàstric (CG) és actualment el vuitè tipus de càncer més prevalent a la Unió Europea on, segons les estimacions, el 2018 es calculen 80.211 casos diagnosticats en ambdós sexes amb una taxa estimada d'incidència estandarditzada per edat de 6,4 casos per cada 100.000 habitants. En el cas d'Espanya, segons dades d'incidència i mortalitat del projecte GLOBOCAN i de l'Observatori Europeu del Càncer, se situa en novè lloc, després del càncer de bufeta i el càncer uterí, pel que fa a freqüència. Els objectius d'aquesta guia són: Desenvolupar, difondre, implementar i avaluar resultats de l'ICO-ICSPraxi de càncer gàstric i d'unió esofagogàstrica. Disminuir la variabilitat terapèutica entre els pacients tractats als diferents centres d'aquesta institució. Implementar els resultats de la terapèutica en els pacients amb càncer gàstric i d'unió esofagogàstrica tractats d'acord amb les recomanacions d'aquesta guia.El cáncer gástrico (CG) es actualmente el octavo tipo de cáncer más prevalente en la Unión Europea donde, según las estimaciones, el 2018 se calculan 80.211 casos diagnosticados en ambos sexos con una tasa estimada de incidencia estandarizada por edad de 6,4 casos por cada 100.000 habitantes. En el caso de España, según datos de incidencia y mortalidad del proyecto GLOBOCAN y del Observatorio Europeo del Cáncer, se sitúa en noveno lugar, después del cáncer de vejiga y el cáncer uterino, en cuanto a frecuencia. Los objetivos de esta guía son: Desarrollar, difundir, implementar y evaluar resultados del ICO-ICSPraxi de cáncer gástrico y de unión esofagogástrica. Disminuir la variabilidad terapéutica entre los pacientes tratados en los diferentes centros de esta institución. Implementar los resultados de la terapéutica en los pacientes con cáncer gástrico y de unión esofagogástrica tratados de acuerdo con las recomendaciones de esta guía.Gastric cancer (GC) is currently the eighth most prevalent type of cancer in the European Union where, according to estimates, 80,211 cases diagnosed in both sexes are estimated at an estimated rate of incidence standardized by age of 6.4 cases per 100,000 people. In the case of Spain, according to the incidence and mortality data of the GLOBOCAN project and the European Cancer Observatory, it is placed ninth, after bladder cancer and uterine cancer, as it happens frequently. The objectives of this guide are: Developing, disseminating, implementing and evaluating the results of the ICO-ICSPraxi of gastric cancer and esophagogastric binding. Decrease the therapeutic variability between patients treated at the different centers of this institution. Implement the results of therapeutic treatment in patients with gastric cancer and esphagogastric binding treated in accordance with the recommendations of this guide

Manejo nutricional de la esclerosis lateral amiotrófica: resumen de recomendaciones

La esclerosis lateral amiotrófica (ELA) es una enfermedad neurodegenerativa que se caracteriza por debilidad muscular y discapacidad progresivas que acaban produciendo fallo respiratorio y disfagia que conducen a la muerte. El término surge de la combinación de los hallazgos clínicos, caracterizados por la atrofia muscular (amiotrofia), y los hallazgos anatomopatológicos con gliosis y esclerosis del área dorsolateral de la médula espinal, entre otros (1). La ELA es la enfermedad más común de las enfermedades de la motoneurona. Su incidencia global es de 1,5 a 2,7 nuevos casos/100.000 habitantes/año, con una prevalencia media de 2,7 a 7,4 casos/100.000 habitantes (2). En España, según la Sociedad Española de Neurología, se diagnostican tres nuevos casos cada día, lo que supone una incidencia anual de 1/100.000 habitantes y una prevalencia de 3,5/100.000 (3)

Home Parenteral Nutrition in Spain, 2015. Home and Ambulatory Artificial Nutrition (NADYA) Group report

Aim: To communicate the results of the Spanish Home Parenteral Nutrition (HEN) registry of the NADYA-SENPE group for the year 2015.Material and methods: Data was recorded online by NADYA group collaborators that were responsible of the HPN follow-up from 1st January to 31st December 2015.Results: Two hundred and thirty-six patients with 243 episodes of NPD were recorded from 40 hospitals. This represents a rate of 5.08 patients/million habitants for 2015. The most frequent pathology in adults was other (26.3%) followed by palliative oncological (21.6%). The most common complication was catheter-related sepsis which presented a rate of 0.53 infections/1,000 days of HPN. Sixty-four episodes were finished; the main cause was death (43.7%) and resuming to oral via (32.8%).Conclusions: we find increasing centers and professional partners, responding to the progressively more patients with parenteral nutrition support at home. The main indications for the establishment of NPD and causes termination of treatment remain stable

COVID-19 infection in patients on long-term home parenteral nutrition for chronic intestinal failure

International audienceRationale: To investigate the incidence and the severity of COVID-19 infection in patients on long-term home parenteral nutrition (HPN) for chronic intestinal failure (CIF).Methods: Period of observation, from March 1st 2020 to March 1st 2021. Inclusion criteria: patients included in the database since 2015 and still on HPN on March 1st 2020; patients included in the database during the period of observation. Data recorded on March 1st 2021: 1) occurrence of infection since the beginning of pandemic (yes, no, unknown); 2) infection syndrome (asymptomatic, mild-no hospitalization, moderate-hospitalization no-ICU, severe-hospitalization in ICU); 3) vaccination (yes, no, unknown); 4) patient outcome at March 1st 2021: still on HPN, weaned form HPN, deceased, lost to follow up. Statistics by Pearson Chi-Square.Results: 68 centres from 23 countries included 4680 patients; COVID-19 data were available for 55.1% of patients. The cumulative incidence of infection was 9.7% in the total group and ranged from 0% to 21.9% among countries. Infection syndrome was asymptomatic 26.7%, mild 32.0%, moderate 36.0%, severe 5.2%. Vaccination status was unknown 62.0%, non-vaccinated 25.2%, vaccinated 12.8%. Infection rate was lower in pediatric patients (p=0.03) and in those with cancer (p=0.03). In the group of the deceased patients, a higher incidence of infection (p=0.04), a more severe degree of infection syndrome (p<0.001) and a lower percentage of vaccination (p=0.01) were observed.Conclusion: In patients with CIF, the incidence of COVID-19 infection differed greatly among countries and was asymptomatic or with mild symptoms in most cases. COVID infection, severity of infection and vaccination status were associated with a higher risk of death